Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma

(2022) Hidenori Machino et al.   Communications Biology

The future of targeted kinase inhibitors in melanoma

(2022) Signe Caksa et al.   PHARMACOLOGY & THERAPEUTICS

Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

(2021) Justine S. Paradis et al.   CLINICAL CANCER RESEARCH

Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold

(2021) Ricardo A. M. Serafim et al.   JOURNAL OF MEDICINAL CHEMISTRY

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

(2021) Paul Nathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma

(2020) Alison M. Kurimchak et al.   Science Signaling

Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma

(2020) Jessica LF Teh et al.   MOLECULAR CANCER THERAPEUTICS

Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

(2020) Tyler D. Hitchman et al.   CLINICAL CANCER RESEARCH

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors

(2020) Anna Han et al.   ONCOGENE

Functional characterization of uveal melanoma oncogenes

(2020) Jiafang Ma et al.   ONCOGENE

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

(2019) Vivian Chua et al.   EMBO Molecular Medicine

Mapping the Human Kinome in Response to DNA Damage

(2019) Michel Owusu et al.   Cell Reports

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK

(2019) Xiaodong Feng et al.   CANCER CELL

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo

(2019) Fangfang Li et al.   Acta Pharmaceutica Sinica B

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

(2018) Richard D. Carvajal et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

(2018) Dominic Lapadula et al.   MOLECULAR CANCER RESEARCH

GENCODE reference annotation for the human and mouse genomes

(2018) Adam Frankish et al.   NUCLEIC ACIDS RESEARCH

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma

(2017) Vivian Chua et al.   MOLECULAR CANCER RESEARCH

Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics

(2017) Fiona P. Bailey et al.   Pigment Cell & Melanoma Research

Metastatic disease from uveal melanoma: treatment options and future prospects

(2016) Richard D Carvajal et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

(2014) Xiaodong Feng et al.   CANCER CELL

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

(2014) Richard D. Carvajal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

ERM proteins in cancer progression

(2014) J. Clucas et al.   JOURNAL OF CELL SCIENCE

Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

(2013) G. Ambrosini et al.   MOLECULAR CANCER THERAPEUTICS

A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway

(2013) Morvarid Mohseni et al.   NATURE CELL BIOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation

(2009) N. V. Belkina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma

(2008) S. Bakalian et al.   CLINICAL CANCER RESEARCH

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE